Journal Watch · Frontiers in Immunology · 2026
CheckDyn: a multi-cohort computational framework for profiling treatment-induced immune checkpoint dynamics and predicting adaptive resistance to immune checkpoint blockade.
These findings establish a consistent transcriptional signature of compensatory checkpoint upregulation during ICB therapy and provide a data-driven framework for early identification of adaptive resistance that warrants external prospective validation.
TL;DR
These findings establish a consistent transcriptional signature of compensatory checkpoint upregulation during ICB therapy and provide a data-driven framework for early identification of adaptive resistance that warrants external prospective validation.
Key findings
- An ensemble classifier combining logistic regression and random forest on pre-to-post expression deltas achieved an area under the receiver operating characteristic curve (AUC) of 0.812 (95% CI: 0.694-0.930; 5-fold cross-validated AUC = 0.806) for adaptive resistance prediction across n = 59 patients with available response annotations.
- These findings establish a consistent transcriptional signature of compensatory checkpoint upregulation during ICB therapy and provide a data-driven framework for early identification of adaptive resistance that warrants external prospective validation.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Paired Wilcoxon signed-rank testing and linear mixed-effects meta-analysis identified LAG3 (log<sub>2</sub>FC = 0.596, padj = 0.015), PDCD1 (log<sub>2</sub>FC = 0.810, padj = 0.003), TOX2 (log<sub>2</sub>FC = 0.605, padj = 0.003), CD274 (log<sub>2</sub>FC = 0.402, padj = 0.015), and IDO1 (log<sub>2</sub>FC = 0.381, padj = 0.026) as consistently upregulated post-treatment across cohorts. Co-expression network analysis revealed extensive rewiring, with ENTPD1 (ΔDegree = +0.297) emerging as the largest hub-degree shift, suggesting a shift toward metabolic immune suppression. Temporal trajectory modeling showed that all 38 checkpoint genes followed linear upregulation trajectories, with PDCD1 and LAG3 carrying the steepest slopes.
Full abstract (original)
Background: Adaptive resistance limits durable benefit from immune checkpoint blockade (ICB) in the majority of cancer patients, yet the transcriptomic dynamics of the broader checkpoint landscape during treatment remain poorly characterized across tumor types. Here we present CheckDyn, a multi-cohort computational framework that profiles paired pre- and post-treatment transcriptomes to quantify treatment-induced changes across 38 immune checkpoint and exhaustion-associated genes and to predict adaptive resistance. We integrated publicly available RNA-seq and scRNA-seq data from 64 paired tumor samples spanning melanoma, basal cell carcinoma, and non-small-cell lung cancer (GSE91061, GSE120575, GSE123813, GSE176021), applying pseudo-bulk aggregation, Z-score batch correction, and Stouffer meta-analysis for cross-cohort harmonization.
What they did: Paired Wilcoxon signed-rank testing and linear mixed-effects meta-analysis identified LAG3 (log<sub>2</sub>FC = 0.596, padj = 0.015), PDCD1 (log<sub>2</sub>FC = 0.810, padj = 0.003), TOX2 (log<sub>2</sub>FC = 0.605, padj = 0.003), CD274 (log<sub>2</sub>FC = 0.402, padj = 0.015), and IDO1 (log<sub>2</sub>FC = 0.381, padj = 0.026) as consistently upregulated post-treatment across cohorts. Co-expression network analysis revealed extensive rewiring, with ENTPD1 (ΔDegree = +0.297) emerging as the largest hub-degree shift, suggesting a shift toward metabolic immune suppression. Temporal trajectory modeling showed that all 38 checkpoint genes followed linear upregulation trajectories, with PDCD1 and LAG3 carrying the steepest slopes.
Results & conclusions: An ensemble classifier combining logistic regression and random forest on pre-to-post expression deltas achieved an area under the receiver operating characteristic curve (AUC) of 0.812 (95% CI: 0.694-0.930; 5-fold cross-validated AUC = 0.806) for adaptive resistance prediction across n = 59 patients with available response annotations. These findings establish a consistent transcriptional signature of compensatory checkpoint upregulation during ICB therapy and provide a data-driven framework for early identification of adaptive resistance that warrants external prospective validation.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1847297 · PubMed 42292485.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
These findings establish a consistent transcriptional signature of compensatory checkpoint upregulation during ICB therapy and provide a data-driven framework for early identification of adaptive resistance that warrants external prospective validation.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Paired Wilcoxon signed-rank testing and linear mixed-effects meta-analysis identified LAG3 (log<sub>2</sub>FC = 0.596, padj = 0.015), PDCD1 (log<sub>2</sub>FC = 0.810, padj = 0.003), TOX2 (log<sub>2</sub>FC = 0.605, padj = 0.003), CD274 (log<sub>2</sub>FC = 0.402, padj = 0.015), and IDO1 (log<sub>2</sub>FC = 0.381, padj = 0.026) as consistently upregulated post-treatment across cohorts.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1847297. PubMed ID: 42292485. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/checkdyn-a-multi-cohort-computational-framework-for-profiling-treatment-847297/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides